Exenatide and Basal Insulins Use in the Real Setting: an Observational Study in Patients With Type 2 Diabetes

CompletedOBSERVATIONAL
Enrollment

888

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

exenatide

subcutaneous injection, 5mcg or 10mcg, twice a day

DRUG

basal insulin

subcutaneous injection, dosing according to physician's clinical judgment

Trial Locations (50)

Unknown

Research site, Acquaviva delle Fonti

Research site, Anzio

Research site, Bassano del Grappa

Research site, Bologna

Research site, Brindisi

Research site, Cagliari

Research site, Campi Salentina

Research site, Casarano

Research site, Caserta

Research site, Cesena

Research site, Chieri

Research site, Cisternino

Research site, Copertino

Research site, Cremona

Research site, Distretto Vittoria

Research site, Fermo

Research site, Ferrara

Research site, Fidenza

Research site, Florence

Research site, Forlì

Research site, Genova

Research site, Germaneto

Research site, Lecce

Research site, Livorno

Research site, Lucca

Research site, Manfredonia (Le)

Research site, Mariano Comense

Research site, Messina

Research site, Milan

Research site, Monza

Research site, Napoli

Research site, Novara

Research site, Olbia

Research site, Palermo

Research site, Palmi

Research site, Parma

Research site, Pavia

Research site, Pisa

Research site, Potenza

Research site, Rimini

Research site, Roma

Research site, Rossano Scalo

Research site, Salerno

Research site, San Giovanni Rotondo

Research site, Schio

Research site, Sesto San Giovanni

Research site, Siena

Research site, Treviso

Research site, Trieste

Research site, Varese

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

lead

AstraZeneca

INDUSTRY